MedTrace Logo

28-day Repeat Dose Study of GSK573719

NCT01030965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719 125mcg

125mcg once-daily

DRUG

GSK573719 250mcg

250mcg once-daily

DRUG

GSK573719 500mcg

500mcg once-daily

DRUG

Placebo

once-daily

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-15
Primary Completion
2010-07-04
Completion
2010-07-04

Countries

  • United States
  • Estonia
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030965 on ClinicalTrials.gov